

## Neal Goodwin Appointed as CSO to Lead Customer-centric Innovation

January 14, 2021

Expanded R&D and product development support to help therapeutics developers get to market faster



HOLLISTER, Calif., January 14, 2021 - Teknova, a leading manufacturer of cell culture media and supplements, purification buffers, and molecular biology reagents—welcomes Dr Neal Goodwin as Chief Scientific Officer (CSO). Neal brings 20 years' experience in biotechnology and therapeutics, with tenures including CSO of Machavert Pharmaceuticals, Vice President of Corporate Research Development for Champions Oncology (NASDAQ: CSBR) and co-founder and former CSO of ProNAi Therapeutics (now Sierra Oncology; NASDAQ: SRRA). As CSO at Teknova, Neal will expand the company's research and development capabilities and lead market outreach for innovative products, driving growth in emerging markets and providing greater product development support to customers in the therapeutics sector.

"I'm excited to join Teknova at this moment in the company's growth," Goodwin said. "Teknova is a unique and incredibly nimble company able to respond quickly to customer needs and develop, manufacture, and ship custom GMP products at unprecedented speed." Since the appointment of Stephen Gunstream as CEO at the end of 2019, Teknova has been rapidly enhancing its support for the therapeutics sector, and a vital part of that is having a world-class R&D department. "I'm delighted to be leading the charge in this area and look forward to developing best-in-class solutions for our customers and driving Teknova's expansion in exciting emerging markets such as cell and gene therapies," Goodwin added.

On Goodwin's appointment, Gunstream said, "We're delighted to have Neal join us as CSO. At Teknova, we keep our focus firmly on our customers' needs. A strong R&D department is crucial to be able to quickly respond with the innovative products and the right support as our customers progress from R&D, through product development, to commercialization. Essentially, we are a partner that handles reagent optimization to deliver GMP products manufactured to specific needs, enabling our customers to focus on getting their products to market as quickly as possible. Neal's wealth of experience in this area will be of tremendous benefit to the company and all our customers."

## About Teknova

Teknova is expediting clinical breakthroughs in the life sciences by providing custom products and reagents for bioprocessing, bioproduction, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high quality, custom, made-to-order products on short turnaround times and at scale, across all stages of development, including commercialization.

Investor Contacts Matt Lowell Chief Financial Officer <u>matt.lowell@teknova.com</u> +1 831 216-1830

Sara Michelmore MacDougall <u>smichelmore@macbiocom.com</u> +1 781-235-3060

Media Contact Matthew Corcoran MacDougall <u>mcorcoran@macbiocom.com</u> +1 617-866-7350